GGrantIndex
Sort

16,179 grants matching malaria

DCTD Biopharmaceutical Development

$5,333,006
David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2014 · CA

VTEU Supplement

$5,179,983
Karen L. Kotloff · University Of Maryland Baltimore · UM1 · FY2021 · AI

Malaria Vaccine Production and Support Services

$5,173,244
Kathleen Kootz · Science Applications International Corp · N01 · FY2010 · AI

Biodefense and Emerging Infectious Disease Vaccine Studies

$5,127,139
Julie E. Ledgerwood · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI

CoVPN - COVID Countermeasures

$5,088,428
Ann R Falsey · University Of Rochester · UM1 · FY2020 · AI

PRECLINICAL DEVELOPMENT OF MMV609, A SECOND-GENERATION ATP4I, FOR MALARIA

$5,072,634
Regents Of The University Of Minnesota · · FY2025 · Defense Health Agency

Infectious Disease Genomics: Pathogen Evolution, Emergence, and Host Interaction

$5,063,540
Bruce W. Birren · Broad Institute, Inc. · U19 · FY2017 · AI

Malaria Vaccines: Pfs25-rEPA and Pfs230-rEPA

$5,020,301
Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI

Development of Pre-Erythrocytic Malaria Vaccines

$5,012,423
Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI

IID Vaccine Evaluation and Development

$5,000,000
David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2014 · CA

Broad Institute Comprehensive Screening Center

$5,000,000
Stuart L Schreiber · Broad Institute, Inc. · U54 · FY2012 · HG

Biodefense and Emerging Infectious Disease Vaccine Studies

$4,962,764
Julie E. Ledgerwood · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI

Structural Genomics of Pathogenic Protozoa

$4,868,309
University Of Washington · P50 · FY2003 · GM

DEVELOPMENT OF SAFER DRUGS FOR MALARIA AND LEISHMANIASIM IN US TROOPS, CIVILIAN PERSONNEL AND TRAVELERS

$4,801,212
The University Of Mississippi · · FY2008 · Department of the Army

Immunization against Multidrug-resistant Pathogens: Activating T Cell Immunity (IMPACT-CETR)

$4,776,780
Richard Malley · Boston Children'S Hospital · U19 · FY2025 · AI

MALARIA VACCINE PRODUCTION AND SUPPORT SERVICES

$4,730,568
Kathleen Kootz · Science Applications International Corp · N01 · FY2012 · AI

Vaccine and Treatment Evaluation Units

$4,699,209
Nadine Georges Rouphael · Emory University · UM1 · FY2022 · AI

Biodefense/Emerging Infection Vaccine Studies

$4,674,742
Julie E. Ledgerwood · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI

CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine - LC3

$4,637,125
Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI

Vanderbilt Vaccine and Treatment Evaluation Unit

$4,613,138
Clarence Buddy Creech · Vanderbilt University Medical Center · UM1 · FY2021 · AI

Data Coordinating Center for the Sickle Cell Disease Clinical Research Network

$4,527,221
Sonja M McKinlay · New England Research Institutes, Inc. · U10 · FY2008 · HL

Systems Analysis Vaccine Responses in Healthy and Hyporesponsive Humans

$4,499,507
Anna Karolina Palucka · Baylor Research Institute · U19 · FY2010 · AI

Structural Genomics of Pathogenic Protozoa

$4,435,865
University Of Washington · P50 · FY2001 · GM

Systematic Development of Antiretroviral Intravaginal Rings for HIV Prevention

$4,434,672
Marc Michael Baum · Oak Crest Institute Of Science · U19 · FY2016 · AI

Advancing Genomic Technologies to Combat Infectious Disease: Mapping Dynamics within Single Cells, Individual Hosts, and Global Populations

$4,400,000
Bruce W. Birren · Broad Institute, Inc. · U19 · FY2019 · AI